The continuous glucose monitoring device market size was USD 5 billion in 2023, estimated at USD 5.36 billion in 2024 and is anticipated to reach around USD 10.65 billion by 2034, expanding at a CAGR of 7% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Continuous Glucose Monitoring (CGM) Device Market
5.1. COVID-19 Landscape: Continuous Glucose Monitoring (CGM) Device Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Continuous Glucose Monitoring (CGM) Device Market, By Component
8.1. Continuous Glucose Monitoring (CGM) Device Market, by Component Type, 2024-2034
8.1.1. Transmitters
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Receivers
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Sensors
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Integrated Insulin Pumps
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Continuous Glucose Monitoring (CGM) Device Market, By End User
9.1. Continuous Glucose Monitoring (CGM) Device Market, by End User, 2024-2034
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Home Healthcare
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Continuous Glucose Monitoring (CGM) Device Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Component (2021-2034)
10.1.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Component (2021-2034)
10.2.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Component (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Component (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Component (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Component (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Component (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Component (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Component (2021-2034)
10.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Component (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Component (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2034)
Chapter 11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Dexcom, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. A. Menarini Diagnostics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Echo Therapeutics, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. GlySens Incorporated
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Johnson & Johnson
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medtronic plc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Senseonics Holdings, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. F. Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ypsomed
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample